scholarly journals Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy

2005 ◽  
Vol 4 (5) ◽  
pp. 548-554 ◽  
Author(s):  
Erlinda E. Embuscado ◽  
Daniel Laheru ◽  
Francesca Ricci ◽  
Ki Jung Yun ◽  
Sten de Boom Witzel ◽  
...  
2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Bo Ren ◽  
Jinshou Yang ◽  
Chengcheng Wang ◽  
Gang Yang ◽  
Huanyu Wang ◽  
...  

Abstract Background Pancreatic cancer’s poor prognosis is caused by distal metastasis, which is associated with epigenetic changes. However, the role of the 3D epigenome in pancreatic cancer biology, especially its metastasis, remains unclear. Methods Here, we developed high-resolution 3D epigenomic maps of cells derived from normal pancreatic epithelium, primary and metastatic pancreatic cancer by in situ Hi-C, ChIP-seq, ATAC-seq, and RNA-seq to identify key genes involved in pancreatic cancer metastasis Results We found that A/B compartments, contact domains, and chromatin loops changed significantly in metastatic pancreatic cancer cells, which are associated with epigenetic state alterations. Moreover, we found that upregulated genes, which were located in switched compartments, changed contact domains, and metastasis-specific enhancer-promoter loops, were related to cancer metastasis and poor prognosis of patients with pancreatic cancer. We also found that transcription factors in specific enhancer-promoter loop formation were also associated with metastasis. Finally we demonstrated that LIPC, looped to metastasis-specific enhancers, could promote pancreatic cancer metastasis. Conclusions These results highlight the multiscale 3D epigenome reprogramming during pancreatic cancer metastasis and expand our knowledge of mechanisms of gene regulation during pancreatic cancer metastasis.


2009 ◽  
Vol 133 (3) ◽  
pp. 413-422 ◽  
Author(s):  
Shinichi Yachida ◽  
Christine A. Iacobuzio-Donahue

Abstract Context.—Metastatic disease is the most critical determinant of resectability of pancreatic cancer and accounts for the poor outcome of patients with this disease. Thus, a better understanding of metastatic pancreatic cancer will afford new opportunities for therapeutic intervention. Objective.—To summarize and discuss the current understanding of the clinical and molecular features of metastatic pancreatic cancer. Data Sources.—Published literature on advanced stage pancreatic cancer, pancreatic cancer metastasis, and autopsy findings in patients with pancreatic cancer. Conclusions.—In the clinical setting, it can be difficult to distinguish a metastatic pancreatic carcinoma from primary neoplasms in the liver, lung, or ovary. However, immunolabeling for DPC4 protein as part of a diagnostic panel is useful for making this distinction. Emerging data from a variety of investigators now indicate that overexpression of EphA2, loss of DPC4 and MKK4, and aberrant activation of the Hedgehog signaling pathway are associated with metastatic propensity of pancreatic cancers, providing novel therapeutic targets for the most lethal stage of this disease.


2013 ◽  
Vol 13 (4) ◽  
pp. 467-478 ◽  
Author(s):  
C. Liu ◽  
H. Cheng ◽  
S. Shi ◽  
X. Cui ◽  
J. Yang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document